AVAX Technologies Report issue

For profit Phase 2 Phase 3
Founded: Philadelphia PA United States (1990)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
1998
NCT00003715
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Lung Neoplasms (Phase 2)

Melanoma (Phase 3)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 8